Posted on 9 月 5, 20249/5/24
The Promise of a Direct-to-Patient Model – Breaking Down What’s Really Needed for Better Patient Access
Posted on 8 月 5, 20248/5/24
Understanding IDNs and What They Mean to the Pharmaceutical Industry–Q&A with Greg Skalicky
Posted on 7 月 16, 20247/16/24
Maximizing Medical Affairs and MSL Impact: How Choosing a Strategic Launch Partner Propels Success
Posted on 6 月 28, 20246/28/24
European Parliament’s Revision of the General Pharmaceutical Legislation
Posted on 4 月 16, 20244/16/24
Navigating Pharmaceutical Success: Harnessing Data Analytics and Predictive Modeling
Posted on 3 月 27, 20243/27/24
Growing EVERSANA’s Value & Evidence Global Footprint with the Additions of Monique Martin, Pamela Vo and Deepika Thakur
Posted on 1 月 3, 20241/3/24
Transforming Pharmaceutical Commercialization: Eight Key Insights for Success
Posted on 11 月 15, 202311/15/23
Incorporating Medical Science Liaisons Early and Often Amplifies Impact and Delivers Stronger Patient Outcomes
Posted on 8 月 21, 20238/21/23